Biotech catalyst, news and analysis PDUFA tracker
Replimune Group Inc
The biotech calendar is entering a dense FDA-driven window, with three Nasdaq-listed names standing out for very different reasons: a renal-disease PDUFA decision watch, a rare-disease cell therapy advisory committee, and an oncology BLA resubmission that has put accelerated approval back in focus.
ASCO 2026: why these three stories matter to the market
ASCO 2026 is producing many important oncology updates, but for traders the key question is not simply which dataset is scientifically interesting. The more useful question is: which dataset can change a regulatory path, reduce or increase perceived risk, alter the probability of approval, move commercial timing or change how the market values a biotech company?
Through that lens, three st
Replimune’s May 29, 2026 announcement reopens one of the most controversial oncology regulatory stories of the year. RP1 is not approved, and a new PDUFA date has not yet been announced, but the company says FDA has aligned on a path for resubmission and urgent reconsideration of the BLA for RP1 plus nivolumab in advanced melanoma.
The FDA’s second no on RP1 plus nivolumab in advanced melanoma does not look like a simple administrative delay. It is a rejection that hits the core regulatory thesis, reopens the debate around the program’s near-term value and forces a broader reassessment of the Replimune story as a strategic reset rather than a delayed approval thesis.
A full editorial deep dive on the three most interesting April biotech FDA setups still ahead: Replimune, Travere Therapeutics and Grace Therapeutics. Each story carries a different kind of risk. Replimune is the credibility test after a prior CRL. Travere is the commercial expansion test for a product that already sells. Grace is the classic small-cap binary setup where one approval could change the company’s profile very quickly.
Replimune is not a “nice little pipeline story” going into spring 2026. It is a high-beta, high-volatility, very real binary event name whose valuation, narrative, financing flexibility, and strategic credibility are all tied in a major way to one date: April 10, 2026. That is the FDA target action date for the resubmitted BLA for RP1 plus nivolumab in advanced melanoma after anti-PD-1 failure. The market already treated the October 2025 acceptance of the resubmission as a major event, and for good reason. This was not a routine update. It was the market’s signal that the story had gone from post-CRL damage control back to live regulatory possibility.
